Share |

T-Ray Science, Inc. Files US Non Provisional Patent

September 22, 2010 at 12:37 am

Vancouver, Canada: T-Ray Science, Inc. (TSX-V: THZ) announces it has filed a non provisional patent with the U.S. Patent and Trade Mark Office on a Unified Sensing Matrix for a Single Pixel Detector Based on Compressive Sensing (USPTO Serial No. 61/243,559).

T-Ray’s Patent covers a particular process of acquiring a 2D image that allows for higher quality and faster scanning from a Terahertz beam.  The Company is anticipating using the patented process in the development of its portable Skin Cancer Imager.

“T-Ray recognizes the importance of strengthening our patent portfolio”, says T-Ray President and CEO Thomas Braun.  “The signal process covered by this patent complements our existing intellectual property recently licensed from the BC Cancer Agency.”

About T-Ray Science, Inc.

T-Ray Science, Inc. is a medical device company centered on the commercialization of an innovative skin cancer detection system for the early diagnosis and treatment of all significant forms of skin cancer (including: melanoma, basal cell carcinoma and squamous cell carcinoma).

The Company’s patented imaging and spectroscopy technologies are the foundation for the development of its non-invasive, in vivo skin cancer detection and delineation system. This diagnostic device will deliver significant clinical impact by streamlining and optimizing the skin cancer detection process, and will reduce healthcare costs by eliminating the need for most biopsies. The platform technology is extensible to other forms of cancer including gastro-intestinal and cervical cancers.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information contact:

T-Ray Science, Inc.
Thomas Braun, President & CEO      
Telephone: 1-877-605-0507


Forward Looking Statements  
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top